Otsuka, Lundbeck agree to settle antipsychotic drug class action for $4.75M
Pharmaceutical companies Otsuka Canada and Lundbeck Canada have agreed to a proposed $4.75-million settlement in a class action alleging that their antipsychotic drug Rexulti may cause compulsive behaviours, including hypersexuality, compulsive...To view the full article, register now.
Already a subscriber? Click here to view full article